Abstract:Understanding the function of genes and their regulation in tissue homeostasis and disease requires knowing the cellular context in which genes are expressed in tissues across the body. Single cell genomics allows the generation of detailed cellular atlases in human tissues, but most efforts are focused on single tissue types. Here, we establish a framework for profiling multiple tissues across the human body at single-cell resolution using single nucleus RNA-Seq (snRNA-seq), and apply it to 8 diverse, archived, frozen tissue types (three donors per tissue). We apply four snRNA-seq methods to each of 25 samples from 16 donors, generating a cross-tissue atlas of 209,126 nuclei profiles, and benchmark them vs . scRNA-seq of comparable fresh tissues. We use a conditional variational autoencoder (cVAE) to integrate an atlas across tissues, donors, and laboratory methods. We highlight shared and tissue-specific features of tissue-resident immune cells, identifying tissue-restricted and non-restricted resident myeloid populations. These include a cross-tissue conserved dichotomy between LYVE1- and HLA class II-expressing macrophages, and the broad presence of LAM-like macrophages across healthy tissues that is also observed in disease. For rare, monogenic muscle diseases, we identify cell types that likely underlie the neuromuscular, metabolic, and immune components of these diseases, and biological processes involved in their pathology. For common complex diseases and traits analyzed by GWAS, we identify the cell types and gene modules that potentially underlie disease mechanisms. The experimental and analytical frameworks we describe will enable the generation of large-scale studies of how cellular and molecular processes vary across individuals and populations. ### Competing Interest Statement A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. Since 1 August 2020, A.R. has been an employee of Genentech. G.G. was partially funded by the Paul C. Zamecnik Chair in Oncology at the Massachusetts General Hospital Cancer Center. G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect, MSMutSig, MSIDetect, POLYSOLVER and TensorQTL. G.G. is a founder, consultant, and holds privately-held equity in Scorpion Therapeutics. F.A. is an inventor on a patent application related to TensorQTL. E.D. is an employee of Bristol Myers Squibb. O.R.R. is an employee of Genentech. O.R.R. and A.R. are co-inventors on patent applications filed at the Broad related to single cell genomics.

A validated single-cell-based strategy to identify diagnostic and therapeutic targets in complex diseases

Single-cell Eqtlgen Consortium: a Personalized Understanding of Disease

Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation.

Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Single-cell Transcriptome in the Identification of Disease Biomarkers: Opportunities and Challenges

Functional phenotyping of genomic variants using multiomic scDNA-scRNA-seq

Single-nucleus Cross-Tissue Molecular Reference Maps to Decipher Disease Gene Function

LifeTime and Improving European Healthcare Through Cell-Based Interceptive Medicine.

The Single-Cell Eqtlgen Consortium

Applications of single-cell RNA sequencing in drug discovery and development

Integrated Single Cell Analysis of Human Lung Fibrosis Resolves Cellular Origins of Predictive Protein Signatures in Body Fluids

Advancing precision medicine through single‐cell sequencing: Insights and implications

A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets

Prioritization and functional validation of target genes from single-cell transcriptomics studies

Identification of Multi-landscape and Cell Interactions in the Tumor Microenvironment through High-Coverage Single-Cell Sequencing

Exploiting Single-Cell Tools in Gene and Cell Therapy

Potentials of single-cell biology in identification and validation of disease biomarkers.

Single‐cell profiling for advancing birth defects research and prevention

Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification

Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens